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Severe AS 4.197 [1.6, 11.1] 1.4344 0.4944 8.4165 0.0037
Age (years)* 1.49 [1.1, 2] 0.0399 0.0154 6.7363 0.0094
LVEF (%)** 1.37 [1.0, 1.8] -0.0314 0.0137 5.2349 0.0221
*continuous variable followed in 10 year intervals
**continuous variable followed in -10% intervals
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Numbers Needed to Treat Patients and Numbers Needed to Save Money. The
Clinical and Economic Impact of TAVI and ICD face to face
Flavio L. Ribichini1, Gabriele Pesarini2, Corrado Vassanelli2
1Università di Verona, Verona, Italy, 2University of Verona, Verona, Italy
Background: Ageing, and the ever-increasing complexity of medical care requires an
accurate assessment of the clinical advantages of treatments in relation to economic
burden. A highly rated and conceptually simple indicator of this "weighed" inter-
vention is the number needed to treat (NNT). Treating inoperable aortic stenosis
patients with transcatheter aortic valve implantation (TAVI), as deﬁned in the
PARTNER trial, yields an NNT to save 1 life at 1 year of 5 (and 3.7 at 3 years). Such
a formidable indicator of a "therapeutic-effort-to-clinical-yield" has never been so
categorically proven in the most pivotal endpoint for interventional cardiology, and
has led to a Class-I recommendation for TAVI in the recent European guidelines.
Methods: All European clinical and economic data used to calculate cost-beneﬁt
ratios was derived from publicly available data including peer-reviewed literature and
national payment schedules (GHM for France, G-DRG for Germany, weighted
National/Regional DRG tariffs and TAVI reimbursement.
Results: For the example of ICDs used in secondary prevention, it was estimated that
the mean cost to the payer per death avoided at 1 year was V232,550, V197,098 and
V244,335 for France, Germany and Italy respectively. For TAVI the corresponding
cost per death avoided was V160,090, V150,872 and V122.007. In Italy this is also
compounded by the recent introduction of medical device budget procurement caps.
Conclusions: The clinical data in support of TAVI is now strong and it is calculated
that these impressive results are matched by the economic performance when
comparing against other technologies which are often considered routine in their use.
This argument extends beyond the single comparison of TAVI and ICDs, and we
present here further analysis and examination of NNT as an appropriate measure of
value driven beneﬁts with medical devices.
TCT-731
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) REDUCES
SYMPATHETIC ACTIVITY AND NORMALIZES ARTERIAL
SPONTANEOUS BAROREFLEX IN PATIENTS WITH AORTIC STENOSIS
Nicolas Dumonteil1, Angelica Vaccaro2, Fabien Despas3, Marc Labrunee1,
Bertrand Marcheix1, Elysabeth Lambert4, Murray D. Esler5, Didier Carrié1,
Jean Michel Senard1, Michel Galinier1, Atul Pathak6
1Cardiovascular and Metabolic Pole, Rangueil Hospital, Toulouse, France,
2Metabolic and Cardiovascular Institut, UMR-1048, Toulouse, France, 3Department
of Clinical Pharmacology, Rangueil Hospital, Toulouse, Toulouse, France, 4Human
Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne,
Australia, 5Baker IDI Heart and Diabetes Institute, Melbourne, Australia,
6Cardiovascular and Metabolic Pole, Rangueil Hospital, Toulouse, Toulouse, France
Background: TAVI is an emerging therapeutic option in pts with severe AS at high
risk for open heart surgery.Whether pts with AS have increased sympathetic activity
remains to be established and effects of TAVI on sympathetic nervous system is also
unknown. We directly measured Muscle Sympathetic Nerve Activity (MSNA) in
patients with aortic stenosis (AS) before and after transcatheter aortic valve implan-
tation (TAVI) and compared MSNA with control patients.
Methods: we prospectively enrolled 14 patients with severe symptomatic AS treated
by TAVI. Fourteen control patients matched for age, body mass index and unscathed
of AS were also included. All patients underwent MSNA and arterial baroreﬂex gain
(ABG) assessment at baseline and one week.
Results: Pts with AS had lower BP levels, signiﬁcant increase in MSNA
(61.01.7vs55.41.4 burst/min; p<0.05) and a decrease in ABG(2.130.14 vs
3.320.19 %burst/mmHg; p<0.01) compared to controls. TAVI induced an increase
of BP associated with a signiﬁcant decrease of MSNA (from 61.01.7 to 54.11.0
burst/min; p<0.01) and was associated with a signiﬁcant increase of ABG (from
2.130.14 to 3.490.33 %burst/mmHg; p<0.0). One patient without sympathetic
baroreﬂex improvement was the only one with moderate paravalvular aortic regur-
gitation (PAR).This could be interpreted as a result of pressure-induced change in
afferent baroreceptor nerve activity thus leading to an increase of MSNA through
a baroreﬂex-mediated mechanism.
Conclusions: We report for the ﬁrst time, that pt with AS have elevated sympathetic
nervous system (SNS) activity associated to a decrease in sympathetic baroreﬂex gain
and that TAVI normalizes these parameters. This study provide evidences for a new
beneﬁcial effect of TAVI namely normalization of SNS hyperactivity. Additionally,
knowing the deleterious effect of SNA in other cardiovascular diseases such as
hypertension or CHF, the lack of normalization of SNS in the pt with moderate PAR
could help to understand the relationship noticed between these signiﬁcant regurgi-
tations following TAVI and the worse survival associated, without any evidence of
causality to date. However,this pathophysiological concept would need to be further
evaluated.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-732
Predictors of Aortic Arch Type: Implications in Patients with Severe Aortic
Stenosis Being Evaluated for Transcatheter Aortic Valve Replacement
Rajiv Tayal1, Benjamin LeSar1, Ahmed Seliem2, Spas Kotev3, Alan Weinberg4,
Afroditi Emporelli3, Zafar Iqbal1, Omar Hasan1, Deepa Iyer1, Gurinder Rana1,
Manjusha Anna1, Humayun Iftikhar1, Patricia Panﬁle1, Marc Cohen5, Najam Wasty1
1Newark Beth Israel Medical Center, Newark, NJ, 2Newark Beth Israel, Newark, NJ,
3Newark Beth Israel Medical Center, Newark, NJ, 4Mount Sinai School of Medicine,
New York, NY, 5Mount Sinai School of Medicine, Newark, NJ
Background: Type II and III aortic arches (T2-3AAs) are associated with lower
procedural success and higher embolic complications in catheter based interventions.
No deﬁnitive studies identify the cause of these challenging anatomical variations. We
hypothesize the development of T2-3AAs is related to gravitational pull on the AA
and brachiocephalic vessels by the heart over time therefore patients of advanced age
and with increased left ventricular (LV) mass, such as those with severe aortic stenosis
(AS) should have a higher incidence of T2-3AAs.
Methods: We reviewed 216 CT scans of the chest with contrast on patients that had
a 2D echocardiogram done within 1 year. Of these patients 107 were found to have
severe AS and evaluated for transcatheter aortic valve replacement (TAVR). AA type
was determined by CT, then patient's baseline characteristics and echocardiographic
parameters including, but not limited to LV ejection fraction (LVEF), LV mass, LV
mass index, and relative wall thickness were analyzed. Complete data was available in
163 patients. The relationship between these variables and AA type was then tested in
univariate and multivariate models.
Results: Univariate analysis revealed severe AS, increased age, weight, coronary
artery disease, LV mass, and LV mass index and reduced LVEF were signiﬁcantly
correlated with type II and III AAs, however after multivariate analysis, only severe
AS, increased age, and LVEF remained as independent predictors of AA type.Conclusions: Severe AS is the most powerful predictor of T2-3AAs. Advanced age
and reduced LVEF also have a statistically signiﬁcant independent correlation with
T2-3AAs. This observation may explain the previously demonstrated beneﬁt of the
left subclavian approach in these patients and accordingly may merit further investi-
gation into the adequacy and beneﬁt of axillary access as smaller caliber TAVR
delivery systems become available
TCT-733
Coronary Flow Reserve Pre and Post Transcatheter Aortic Valve Implantation
in Severe Aortic Stenosis: An Invasive Evaluation Study of Coronary Flow
Dynamics.
Anthony C. Camuglia1, Jaffer Syed1, Pallav Garg1, Bob Kiaii1, Michael Chu1,
Philip M. Jones1, Daniel Bainbridge1, Patrick Teefy1
1London Health Sciences Centre, University of Western Ontario, London, Ontario
Background: Transcatheter aortic valve implantation (TAVI) is an evolving
management strategy for patients with aortic valve disease as an alternative to open
aortic valve replacement. Patients with aortic stenosis (AS) have impaired coronary
ﬂow hemodynamics and this may partially explain the mechanism that causes angina
in this condition. We sought to assess the effect of TAVI on coronary ﬂow reserve
(CFR), an established marker of coronary artery hemodynamic function.
Methods: We enrolled patients undergoing TAVI to have CFR invasively assessed
immediately pre- and post-TAVI (at the time of their TAVI procedure) and again at 6
to 12 months. CFR was recorded as a ratio of average peak velocity, pre- and post-
induction of maximal coronary microvascular hyperemia with administration of
intracoronary adenosine. An intracoronary Doppler probe-tipped coronary ﬂow wire
was utilized for the CFR assessment.
Results: 10 patients were enrolled in the study with 8 having the follow-up evaluation
performed. All patients had impaired CFR prior to TAVI (mean CFR 1.53, 95% CI
1.27 - 1.80). At follow-up invasive assessment there was a signiﬁcant increase in CFR
among the patients (mean % increase in CFR pre-TAVI to follow-up of 46.2%, 95%
CI 16.1 – 76.3%, p<0.01) with a mean CFR of 2.18 (95% CI 1.88 – 2.47) at the
follow up assessment. While there was a signiﬁcant change from baseline pre-TAVIacts/POSTER/Aortic Valve Disease and Treatment B223
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ately post TAVI (mean % DCFR pre TAVI to immediately post TAVI 8.6%, 95% CI
-23.0 – 40.3%, p¼0.41).
Conclusions: TAVI does improve coronary ﬂow dynamics as measured by CFR. This
improvement does not occur immediately, but requires a period of time post-TAVI to
manifest. The improvement in coronary ﬂow reserve may represent a mechanism by
which both symptoms and prognosis improve following TAVI.
TCT-734
Percutaneous Implantation of Stent Grafts in the Management of Vascular
Complications in Transfemoral Transcatheter Aortic Valve Implantation
Jaclyn Chan1, Alaide Chieffo2, Roberto Chiesa3, Enrico Maria Marone3,
Daniele Mascia4, Antonio Colombo5
1San Raffaele Scientiﬁc Institute, Milan, N/A, 2San Raffael Scientiﬁc Institute, Milan,
Italy, Milan, Italy, 3San Raffaele Scientiﬁc Institute, Milan, N/A, 4San Raffaele
Scientiﬁc Institute, Milan, N/A, 5EMO GVM Centro Cuore Columbus/San Raffaele
Hospital, Milan, Italy
Background: Vascular complications remain to be the most prevalent adverse event
associated with transfemoral TAVI and related to increased morbidity and mortality.
Percutaneous implantation of stent grafts in the management of access-site related
vascular complications is not widely studied.
Methods: Among 379 patients who underwent TAVI from November 2007 to
December 2011 for severe aortic stenosis, transfermoral access was performed in 314
patients. 10 cases received surgical closure and consequently pure percutaneous
transfemoral TAVI was performed in 304 patients. We described the clinical outcomes
of this patient cohort who developed access-site related vascular complications and
were subsequently managed by percutaneous implantation of stent grafts. We also
compared their baseline clinical and procedural characteristics, as well as in-hospital
outcomes with those without vascular complications.
Results: Access site-related vascular complications occurred in 68 (22%) patients. 8
patients were managed surgically and 18 by manual compression. The remaining 42
patients with access site-related complications were managed by percutaneous means,
in which 29 were treated solely by implantation of stent grafts. Overall, stent graft
implantation was successful in all cases. The rate of VARC-deﬁned endpoints was
similar between patients managed by stent graft implantation and those free of
vascular complications. After a median follow-up of 19.2months, 9 patients under-
went Duplex ultrasonography of the intervened limb and the remaining patients
underwent clinical assessment. Duplex ultrasonography revealed no evidence of
obstructive ﬂow. Moreover, no patient experienced lower limb ischemic symptoms
during follow-up.
Conclusions: Access-site related vascular complications in transfemoral TAVI can be
managed by implantation of stent grafts with an encouraging technical success rate
and safety proﬁle. The clinical outcomes in these patients are similar to those who
have undergone transfemoral TAVI without vascular complications. However, more
dedicated imaging and larger clinical trials are needed to deﬁne the applicability of
stent grafts in the treatment of vascular complications in TAVI.
TCT-735
Can we Predict Post-Procedural Paravalvular Leak After Edwards Sapien
Transcatheter Aortic Valve Implantation?
Yusuke Watanabe1, Bertrand Cormier2, Thierry Lefevre1, Erik Bouvier1,
Kentaro Hayashida1, Bernard Chevalier1, Mauro Romano1, Thomas Hovasse1,
Philippe Garot3, Patrick Donzeau-Gouge1, Arnaud Farge1, Marie-Claude Morice1
1Institut Cardiovasculaire Paris Sud, Générale de Santé, Massy, France, 2Hôpital
Privé Jacques Cartier, Massy, France, 3Institut Cardiovasculaire Paris Sud, Générale
de Santé, Quincy, France
Background: Post-procedural PVL  2 has been shown to be associated with worse
mid-term outcomes after TAVI. Valve calciﬁcation and optimal valve sizing may play
an important role in this setting. This study sought to identify predictive factors of
post-procedural paravalvular leak (PVL) 2 after transcatheter aortic valve implan-
tation (TAVI) with the Edwards valve.
Methods: A total of 176 Edwards TAVI patients (aged 83.47.4 years, Logistic
EuroSCORE 18.812.0, transfemoral 54.5%) who had preprocedural multislice
computed tomography (MSCT) were studied. In order to assess the role of valve
calciﬁcation, a new Valve Calciﬁcation Index (VCI) was deﬁned using MSCT as
aortic root calciﬁcation volume / aortic annulus area. Optimal valve sizing was deﬁned
as the valve diameter / calculated annulus average diameter (CAAD) by MSCT.
Results: After post dilatation, performed in 16.7% of cases, a PVL  2 was
observed in only 12.5% of cases. The 1-year estimated survival of both PVL < 2
and PVL  2 groups were 95.32.1% vs 79.010.8% (log-rank p¼0.02),
respectively. Only the VCI, odds ratio [OR] 2.11, 95% conﬁdence interval [CI] 1.27
to 3.51, p<0.01) and the valve diameter / CAAD (OR 0.57, 95% CI 0.38 to 0.87,
p¼0.01), were identiﬁed as independent predictors of post-procedural PVL  2. A
score predicting post-procedural PVL  2 (PVL score) was determined by assigning
one point when the Valve / CAAD ratio was < 1.05 and one point when VCI was >
2.05, and summing all points accrued. Area under receiver-operator characteristic
curves of PVL score were 0.70 (95% CI 0.58 to 0.82, p<0.01). The incidence of
PVL  2 in patients with a PVL score of 0 was 5.5%, 1 was 16.7% and 2 was
38.5%, respectively.B224 JACC Vol 62/18/Suppl B j October 27–NovemberConclusions: The only predictors of PVL  2 after Edwards valve implantation are
the valve diameter / CAAD and VCI. The use of these two simple parameters, could
become an excellent tool to predict the risk of PVL.
TCT-736
Interim results of the JUPITER Registry on long-term performance and safety of
the Transapical JenaValve
Stephan Ensminger1, Utz Kappert2, Ulrich Franke3, Ardawan Rastan4,
Hendrik Treede5, Florian Rueter6, Walter Eichinger7, Rudiger Lange8,
Thomas de Kroon9, Friedhelm Beyersdorf10, Olaf Wendler11
1Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen,
Germany, 2Heart Center Dresden, University Dresden Hospital TU Dresden,
Dresden, Germany, 3Robert-Bosch-Hospital, Stuttgart, Germany, 4Heartcenter
Rotenburg / Fulda, Rotenburg / Fulda, Germany, 5Hamburg University, Hamburg,
Germany, 6University Hospital Basel, Basel, Switzerland, 7Klinikum Bogenhausen,
Munich, BAVARIA, 8German Heart Center Munich, Munich, Germany, 9St. Antonius
Hospital, Nieuwegein , Netherlands, 10Heart Center Freiburg University, Freiburg,
Baden-Württemberg, 11King's College Hospital, London, United Kingdom
Background: Transcatheter aortic valve implantation (TAVI) has emerged as an
accepted treatment option for high-risk patients with severe aortic stenosis. The
second generation transapical JenaValve with its unique ﬁxation system enabling
anatomically correct positioning received CE-mark in September 2011. This registry
was designed to evaluate long-term safety and efﬁcacy of the transapical JenaValve
TAVI system in high-risk patients in a real world setting.
Methods: The registry will enroll a total of 180 patients undergoing TAVI with the
transapical JenaValve system and will follow them for a period of ﬁve years.
Endpoints are deﬁned according to Valve Academic Research Consortium (VARC)
with the primary endpoint 30-day mortality and secondary endpoints safety, device
success, effectiveness and quality of life at up to 5 years.
Results: In the JUPITER-Registry, so far 56% of the patients, i.e. a total of 101
patients underwent elective TAVI at 11 European centres. Currently procedural
outcome is available on 88 patients (mean age 80.86.1 years; EuroSCORE
24.913.5%), of whom 84 underwent successful TAVI using the JenaValve resulting
in a procedural success of 95.5%. 2 patients were converted to surgical AVR, 2
patients to a valve-in-valve procedure. 30 day all-cause mortality was 14.9%,
cardiovascular mortality 4.7%. TAVI resulted in favourable reduction of mean
transvalvular gradients (40.414.4mmHg vs. 8.14.9mmHg, p< 0.0001). No or trace
paravalvular leakage (PVL) was present in 80.2% of patients, mild PVL in 17.4% and
moderate PVL in 2.3%. None of the patients had severe post procedural aortic
regurgitation (> grade 2). Complete 30-day results according to VARC criteria of 75
% of the patients, i.e. 135 patients will be presented at the conference.
Conclusions: Interim results of the JUPITER registry demonstrate that TAVI using
the JenaValve system results in high procedural success, excellent hemodynamics and
low incidence of paravalvular leakage. Thirty-day mortality in this very high-risk
group is slightly high in this interim analysis, but ﬁnal results remain to be seen when
data for all 180 patients are available.
TCT-737
MONITORING THE LEARNING CURVE AND QUALITY OF CARE IN
TAVI PROCEDURES BY CUSUM ANALYSIS
Alfredo Giuseppe Cerillo1, Michele Murzi1, Massimiliano Mariani1,
Federica Marchi2, Stefano Maffei3, Cataldo Palmieri3, Mattia Glauber1,
Sergio Berti4
1Fondazione Toscana, Massa, Italy, 2fondazione Toscana, Massa, Italy, 3Fondazione
Toscana, massa, Italy, 4fondazione Toscana, massa, Italy
Background: Starting a TAVI program mandates to keep efﬁcacy and safety
competitive in relation to conventional surgery, while implementing a procedure that
requires new skills and close cooperation between different specialties. In this
complex scenario, monitoring the overall and individual performance is essential. The
aim of the present study was to apply control charts (CUSUM curves) to monitor the
performance of the TAVI team and to enhance the quality control for that procedure.
Methods: The ﬁrst 90 patients undergoing TAVI at our institution were prospectively
monitored, using risk-adjusted CUSUM curves. Predicted risks of failure for indi-
vidual patients were derived from the literature. The following endpoints were
considered: (1) Technical device success (TDS); (2) 30-days mortality (HM); (3) 30-
days freedom from adverse events (FAE).
Results: All patients received a Sapien valve via a transapical (43) or transfemoral
(47) approach. median age was 80.6 years, the median Euroscore and STS score were
24.1 and 9.82. The TDS and the HM CUSUM curves showed an initial cluster of 3
(TDS) and 2 (HM) failures in the ﬁrst 12 procedures, probably reﬂecting the traversing
of the learning curve. Consecutively we experienced a period of good performance
and the process came in control at operation number 29 (TDS) and 26 (HM). The FAE
curve behaved similarly, but a steep upward trend was observed starting from patient
38, and the boundary line was crossed at the 45th patient, indicating that the procedure
was going out of control. An internal audit identiﬁed as possible causes of failure an
inappropriate patients' selection and the lack of a dedicated "Post-procedural care"
team. The correction of these problems led to a downward shift of the CUSUM curve,1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
